Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$2.27 - $3.44 $14,437 - $21,878
-6,360 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$1.97 - $2.89 $1,323 - $1,942
-672 Reduced 9.56%
6,360 $17,000
Q4 2020

Feb 16, 2021

BUY
$1.49 - $3.1 $3,137 - $6,528
2,106 Added 42.75%
7,032 $13,000
Q3 2020

Nov 12, 2020

BUY
$1.7 - $2.98 $778 - $1,364
458 Added 10.25%
4,926 $9,000
Q2 2020

Aug 13, 2020

SELL
$1.74 - $3.19 $6,599 - $12,099
-3,793 Reduced 45.91%
4,468 $10,000
Q1 2020

May 14, 2020

SELL
$1.63 - $3.75 $1,630 - $3,750
-1,000 Reduced 10.8%
8,261 $16,000
Q4 2019

Feb 14, 2020

BUY
$1.37 - $1.97 $12,687 - $18,244
9,261 New
9,261 $15,000
Q3 2019

Nov 14, 2019

SELL
$1.26 - $1.77 $7,958 - $11,179
-6,316 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$1.29 - $1.83 $7,482 - $10,614
5,800 Added 1124.03%
6,316 $9,000
Q1 2019

May 15, 2019

BUY
$1.67 - $3.12 $861 - $1,609
516 New
516 $0
Q3 2018

Nov 14, 2018

SELL
$0.7 - $1.58 $73,752 - $166,468
-105,360 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$0.71 - $4.04 $53,538 - $304,644
75,407 Added 251.75%
105,360 $161,000
Q1 2018

Oct 18, 2019

BUY
$3.91 - $7.83 $6,525 - $13,068
1,669 Added 5.9%
29,953 $121,000
Q1 2018

May 15, 2018

BUY
$3.91 - $7.83 $45,934 - $91,986
11,748 Added 71.04%
28,284 $114,000
Q4 2017

Feb 14, 2018

BUY
$3.9 - $7.77 $14,609 - $29,106
3,746 Added 29.29%
16,536 $99,000
Q3 2017

Nov 14, 2017

BUY
$3.83 - $6.07 $48,985 - $77,635
12,790
12,790 $75,000

Others Institutions Holding VTVT

# of Institutions
1
Shares Held
243K
Call Options Held
0
Put Options Held
0

About vTv Therapeutics Inc.


  • Ticker VTVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,483,600
  • Market Cap $1.43B
  • Description
  • vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...
More about VTVT
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.